| US 7,384,926 B2 | ||
| Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma | ||
| Iok-Hou Pang, Grand Prairie, Tex. (US); and Abbot F. Clark, Arlington, Tex. (US) | ||
| Assigned to Alcon, Inc., Hunenberg (Switzerland) | ||
| Filed on May 29, 2007, as Appl. No. 11/754,710. | ||
| Application 11/754710 is a continuation of application No. 10/487122, abandoned, previously published as PCT/US02/27969, filed on Sep. 03, 2002. | ||
| Claims priority of provisional application 60/317225, filed on Sep. 05, 2001. | ||
| Prior Publication US 2007/0225263 A1, Sep. 27, 2007 | ||
| Int. Cl. A61K 31/56 (2006.01) | ||
| U.S. Cl. 514—171 [514/182] | 3 Claims |
| 1. A method for treating glaucoma-related retina or optic nerve damage in a patient, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of at least one non-feminizing estrogen compound, wherein said non-feminizing estrogen compound is selected from the group consisting of estratriene-3-ol, 3,17α-estradiol, estrone, and estriol, and wherein said composition is administered via a method selected from the group consisting of intravitreal injection, intraocular perfusion, periocular injection and sub-Tenon injection. |